The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJOncoAlert Journal Club | Averectal: avelumab after SCRT and chemotherapy in MSS rectal cancer
Ali Shamseddine, MD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the Phase II Averectal study (NCT03503630) of short-course radiotherapy followed by mFOLFOX6 plus avelumab in patients with locally advanced microsatellite stable rectal adenocarcinoma. The regimen demonstrated a promising pathologic complete response rate and high 3-year disease-free survival, with a low incidence of local recurrence.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
